Better Health for All

Fulcrum Therapeutics' core business is entirely devoted to developing therapies for rare genetic diseases, including losmapimod for FSHD, pociredir for sickle cell disease, and novel agents for Diamond-Blackfan anemia.

The investigational product, losmapimod, demonstrated a perfect safety record in its Phase 3 REACH trial, with no treatment-related serious adverse events reported among 260 patients. The company has an expanded access policy for investigational therapies, committing to acknowledge receipt of requests within three business days. Furthermore, Fulcrum Therapeutics agreed to share trial data and biospecimens from the REACH trial with the FSHD Society, demonstrating strong data transparency. The company's expanded access policy outlines a commitment to developing safe and effective treatments for rare and serious diseases, prioritizing clinical trial participation while reserving expanded access for specific unmet medical needs.

Fair Money & Economic Opportunity

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic diseases.

The provided articles confirm its business operations revolve around clinical trials and financial results related to drug development. As the company does not offer lending, deposit, or other financial services to consumers, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business model.

Fair Pay & Worker Respect

Fulcrum Therapeutics communicated a workforce reduction of 29 employees, from 80 to 51 full-time employees, on September 24, 2024, with implementation expected by the end of Q3 2024, incurring approximately $2.0 million in one-time severance costs.

The company adopted a compensation recovery (clawback) policy in November 2023. It maintains a 401(k) plan with a company match, contributing 100% of the first 2% and 50% of the next 4% of employee contributions, with immediate vesting. CEO Alex C. Sapir's total compensation was $1,003,300 in 2024 and $6,990,596 in 2023. The company has a Code of Business Conduct and Ethics, which includes provisions for employees to report violations openly or anonymously without fear of retaliation, and outlines disciplinary actions for non-compliance. Reporting channels include a whistleblower service and a toll-free number. The Compensation and Human Capital Management Committee reviews and evaluates hiring, turnover, promotion trends, diversity, equity, inclusion initiatives, employee engagement, and company culture. 53% of employees approve of CEO Alex Sapir.

Fair Trade & Ethical Sourcing

No information regarding fair trade and ethical sourcing practices, supplier audits, forced or child labor incidents, supply chain traceability, remediation speed, ethical clauses in contracts, high-risk materials, or supplier diversity spend was found in the provided articles.

The documents primarily cover corporate governance, financial reporting, and a code of business conduct and ethics, none of which contained specific data points for the relevant KPIs.

Kind to Animals

No specific, quantifiable evidence was found in the provided articles to assess Fulcrum Therapeutics, Inc. against any of the 'Kind to Animals' KPIs. While one article notes 'Animal Usage: Animal Testing',

this general statement does not provide the specific data points (e.g., volume of animals used, details of an animal testing policy, extent of alternative testing methods, or certifications) required to score against the rubric's quantitative thresholds for any KPI.

No War, No Weapons

The provided articles for Fulcrum Therapeutics, Inc. primarily detail financial performance, regulatory actions, collaborations, and corporate governance. There is no explicit evidence or specific data points within these articles that address any of the KPIs related to arms manufacturing, military contracts, dual-use technology, sales to sanctioned regimes, peacebuilding investments, or any other aspect of the 'No War, No Weapons' value.

Therefore, all KPIs are omitted due to a lack of direct, factual evidence.

Planet-Friendly Business

The provided articles, which include financial reports (Form 10-Q) and a code of business conduct, do not contain specific, quantifiable data points for any of the 'Planet-Friendly Business' KPIs. While the Code of Business Conduct and Ethics mentions compliance with environmental laws,

this is a policy statement and not evidence of actual performance or lack of violations. The financial reports explicitly state the absence of environmental metrics. Therefore, no KPIs can be scored based on the available information.